Navigation Links
Dow AgroSciences' Success Presented to Wall Street
Date:2/12/2008

Company Outlines Ambitious Growth Plans, Technology Leadership

INDIANAPOLIS, Feb. 12 /PRNewswire-FirstCall/ -- The growing technology share of Dow AgroSciences, a wholly owned subsidiary of The Dow Chemical Company (NYSE: DOW), was the focus of a presentation made to investors earlier today by Jerome Peribere, president and CEO of Dow AgroSciences. Peribere was speaking at the Goldman Sachs Agricultural Chemicals Conference in New York City, where he reinforced Dow AgroSciences' technology-based strategy of growing its agricultural chemicals business while developing new biotechnology products and platforms.

"We believe the company with the best technology will ultimately generate the most value," said Peribere. "We are building our capabilities to do exactly that and provide our customers with revolutionary solutions."

He cited numerous examples of the Company's innovation -- from both the chemical and biological sides of the portfolio -- and highlighted the progress of the seeds business during 2007, including growth in the Americas for its corn, cotton, sunflower, and canola product portfolios.

A key move in 2007 was the Company's announcement of its SmartStax(TM) agreement with Monsanto, creating the industry's first eight-gene stack of traits in corn. As a result of this scientific breakthrough, Peribere expects Dow's HERCULEX(TM) insect protection technology to be on approximately 40 percent of U.S. corn acres in the SmartStax launch year of 2010 and on about 60 percent of acres by 2012. This technology package will be further enhanced when Dow AgroSciences launches its Dow Herbicide Tolerance technology in 2012 for corn, and in 2013 for cotton and soybeans.

Peribere concluded that growth for Dow AgroSciences will continue as the Company develops technology leadership, builds a billion-dollar corn business and advances its ag chemical pipeline.

About Dow

With annual sales of $54 billion and 46,000 employees worldwide, Dow is a diversified chemical company that combines the power of science and technology with the "Human Element" to constantly improve what is essential to human progress. The Company delivers a broad range of products and services to customers in around 160 countries, connecting chemistry and innovation with the principles of sustainability to help provide everything from fresh water, food and pharmaceuticals to paints, packaging and personal care products. References to "Dow" or the "Company" mean The Dow Chemical Company and its consolidated subsidiaries unless otherwise expressly noted. More information about Dow can be found at http://www.dow.com

About Dow AgroSciences

Dow AgroSciences LLC, based in Indianapolis, Indiana, USA, is a top-tier agricultural company that combines the power of science and technology with the "Human Element" to constantly improve what is essential to human progress. Dow AgroSciences provides innovative technologies for crop protection, pest and vegetation management, seeds, traits, and agricultural biotechnology to serve the world's growing population. Global sales for Dow AgroSciences, a wholly owned subsidiary of The Dow Chemical Company, are $3.8 billion. Learn more at http://www.dowagro.com.

(TM)Trademark of Dow AgroSciences LLC

SmartStax(TM) is a trademark of Monsanto Company


'/>"/>
SOURCE The Dow Chemical Company
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Dow AgroSciences and Exelixis Plant Sciences Announce Major Research Collaboration, Asset Purchase to Advance Gene Discovery and Validation
2. ThromboGenics Announces Successful Completion of Technology Transfer to Bharat Biotech for Production of Novel Thrombolytic Agent
3. ThromboGenics and BioInvent Announce Successful Completion of Phase I Clinical Trial of the Anticoagulant TB-402
4. EpiStem Successfully Complete First Year of Mucositis Tests for NIH Biodefence Programme
5. Life on Mars pregnancy test successfully launched
6. Of mice and men: new male contraceptives successful in rodents and humans
7. Crux Biomedical Announces First Successful U.S. Implant of Its New Retrievable Inferior Vena Cava (IVC) Filter
8. AMDL to Present its China Success Story at Rodman & Renshaw 9th Annual Healthcare Conference
9. Clinical Study Findings Show Safety and Procedure Success for TopSpin IntraVascular MRI Catheter for the Coronary Arteries
10. ARIUS announces cancer stem cell antibody program successfully completes first toxicology study
11. Rosetta Genomics Announces Initiation of In Vivo Studies Following Successful Completion of First Milestone in MicroRNA-based Therapeutic Program for Liver Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/24/2017)... , ... February 24, 2017 , ... ... procedures can be safely completed in an ambulatory surgery center (ASC) with satisfactory ... procedures and previous two-year TDR studies. , Jake Lubinski, president of AxioMed, ...
(Date:2/24/2017)... , Feb. 24, 2017  Aethlon Medical, Inc. ... note authored by its Chairman and CEO, Jim ... the Munich Security Conference last Saturday, Bill Gates ... could kill more people than nuclear weapons. Mr. Gates ... and U.K. intelligence agencies, that scientific terrorists have access ...
(Date:2/24/2017)... , ... February 24, 2017 , ... FireflySci, Inc is ... in late 2014, FireflySci had the goal of bringing their powerful cuvette ... to shape the path that FireflySci is going on as they add yet another ...
(Date:2/23/2017)... and NEW YORK , Feb. ... Lumeon , a leading digital health company, and ... provider of telemedicine and remote patient monitoring, announce ... telemedicine reimbursements.  DN Telehealth maximizes ... in real-time, extending consultations beyond a physical clinical ...
Breaking Biology Technology:
(Date:2/7/2017)... Zimmer Biomet Holdings, Inc. (NYSE and SIX: ... at the LEERINK Partners 6th Annual Global Healthcare Conference ... February 15, 2017 at 10 a.m. Eastern Time. ... be accessed at http://wsw.com/webcast/leerink28/zbh .  The webcast will ... Biomet,s Investor Relations website at http://investor.zimmerbiomet.com . ...
(Date:2/3/2017)... 2017  Texas Biomedical Research Institute announced that its Board ... as the Institute,s new President and CEO. Dr. Schlesinger ... 2017. He is currently the Chair of the Department of ... Microbial Interface Biology at Ohio State University. "We ... and CEO of Texas Biomed," said Dr. James O. ...
(Date:2/2/2017)... 2017  EyeLock LLC, a market leader of iris-based ... " What You Should Know About Biometrics in the ... authenticity is a growing concern. In traditional schemes, cryptography ... traditional authentication schemes such as username/password suffer from inherent ... offers an elegant solution to the problem of high-security ...
Breaking Biology News(10 mins):